Ashton Thomas Securities LLC Invests $35,000 in Kenvue Inc. (NYSE:KVUE)

Ashton Thomas Securities LLC purchased a new stake in shares of Kenvue Inc. (NYSE:KVUE) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 1,499 shares of the company’s stock, valued at approximately $35,000.

Several other institutional investors and hedge funds also recently bought and sold shares of KVUE. Leo Wealth LLC lifted its position in shares of Kenvue by 0.3% during the third quarter. Leo Wealth LLC now owns 151,611 shares of the company’s stock worth $3,507,000 after acquiring an additional 481 shares in the last quarter. Massmutual Trust Co. FSB ADV lifted its holdings in Kenvue by 6.2% during the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 8,400 shares of the company’s stock worth $194,000 after purchasing an additional 492 shares in the last quarter. Wolff Wiese Magana LLC boosted its stake in Kenvue by 0.7% in the 3rd quarter. Wolff Wiese Magana LLC now owns 76,999 shares of the company’s stock worth $1,781,000 after purchasing an additional 501 shares during the period. Marathon Capital Management grew its holdings in Kenvue by 0.3% during the 2nd quarter. Marathon Capital Management now owns 149,699 shares of the company’s stock valued at $2,722,000 after buying an additional 514 shares in the last quarter. Finally, Poehling Capital Management INC. increased its position in shares of Kenvue by 0.5% during the second quarter. Poehling Capital Management INC. now owns 104,934 shares of the company’s stock valued at $1,908,000 after buying an additional 547 shares during the period. 97.64% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

KVUE has been the subject of a number of analyst reports. UBS Group raised their price objective on shares of Kenvue from $20.00 to $22.00 and gave the company a “neutral” rating in a research report on Wednesday, August 7th. Deutsche Bank Aktiengesellschaft raised their price target on shares of Kenvue from $23.00 to $24.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. JPMorgan Chase & Co. upped their price target on shares of Kenvue from $24.00 to $25.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. Royal Bank of Canada lowered Kenvue from an “outperform” rating to a “sector perform” rating and set a $24.00 price objective for the company. in a research note on Tuesday, September 24th. Finally, Piper Sandler upped their target price on Kenvue from $20.00 to $21.00 and gave the stock a “neutral” rating in a research note on Monday, September 23rd. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $22.64.

Kenvue Stock Performance

NYSE:KVUE opened at $23.13 on Thursday. The company has a market capitalization of $44.35 billion, a price-to-earnings ratio of 42.05, a PEG ratio of 2.15 and a beta of 1.36. The business has a 50 day moving average of $22.72 and a 200 day moving average of $20.62. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. Kenvue Inc. has a 1-year low of $17.67 and a 1-year high of $23.95.

Kenvue (NYSE:KVUE) last posted its quarterly earnings results on Thursday, November 7th. The company reported $0.28 EPS for the quarter, topping the consensus estimate of $0.27 by $0.01. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The firm had revenue of $3.90 billion for the quarter, compared to the consensus estimate of $3.92 billion. During the same period last year, the firm posted $0.31 earnings per share. The business’s revenue was down .4% compared to the same quarter last year. On average, sell-side analysts predict that Kenvue Inc. will post 1.07 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, November 27th. Shareholders of record on Wednesday, November 13th will be given a dividend of $0.205 per share. The ex-dividend date is Wednesday, November 13th. This represents a $0.82 annualized dividend and a yield of 3.55%. Kenvue’s payout ratio is 149.09%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.